Table 3.
Predictors of intentions to use telemedicine after the COVID-19 pandemic.
| Predictor | B (SE) |
95% CI | β | t test (df) | P value | ||||||
| Step 1 | |||||||||||
|
|
Constant | 2.67 (0.48) | 1.73 to 3.61 | Reference | 5.61 (365) | <.001 | |||||
|
|
Telemedicine caseload | 0.74 (0.18) | 0.38 to 1.10 | .21 | 4.04 (365) | <.001 | |||||
|
|
Onset of telemedicine usage | –0.42 (0.16) | –0.73 to –0.12 | –.14 | –2.71 (365) | .007 | |||||
|
|
Age | –0.01 (0.01) | –0.02 to –0.002 | –.09 | –1.68 (365) | .09 | |||||
| Step 2 | |||||||||||
|
|
Constant | 0.97 (0.61) | –0.22 to 2.17 | Reference | 1.60 (363) | .11 | |||||
|
|
Telemedicine caseload | 0.35 (0.18) | 0.001 to 0.71 | .10 | 1.96 (363) | .05 | |||||
|
|
Onset of telemedicine usage | –0.38 (0.15) | –0.67 to –0.09 | –.12 | –2.61 (363) | .009 | |||||
|
|
Age | –0.01 (0.01) | –0.02 to 0.002 | –.07 | –1.53 (363) | .13 | |||||
|
|
Usefulness (general) | 0.40 (0.07) | 0.27 to 0.53 | .31 | 5.93 (363) | <.001 | |||||
|
|
Usefulness (COVID-19) | 0.24 (0.11) | 0.02 to 0.46 | .11 | 2.11 (363) | .04 | |||||
| Step 3 | |||||||||||
|
|
Constant | 0.08 (0.64) | –1.19 to 1.35 | Reference | 0.12 (362) | .90 | |||||
|
|
Telemedicine caseload | 0.35 (0.18) | –0.002 to 0.70 | .10 | 1.96 (362) | .05 | |||||
|
|
Onset of telemedicine usage | –0.33 (0.14) | –0.61 to –0.05 | –.11 | –2.30 (362) | .02 | |||||
|
|
Age | –0.01 (0.01) | –0.02 to 0.002 | –.07 | –1.51 (362) | .13 | |||||
|
|
Usefulness (general) | 0.34 (0.07) | –0.21 to 0.48 | .27 | 5.10 (362) | <.001 | |||||
|
|
Usefulness (COVID-19) | 0.17 (0.11) | –0.05 to 0.40 | .08 | 1.56 (362) | .12 | |||||
|
|
Ease of use | 0.02 (0.005) | 0.01 to 0.03 | .18 | 3.70 (362) | <.001 | |||||
| Step 4 | |||||||||||
|
|
Constant | –1.15 (0.44) | –2.02 to –0.27 | Reference | –2.58 (361) | .01 | |||||
|
|
Telemedicine caseload | 0.34 (0.12) | 0.11 to 0.58 | .10 | 2.84 (361) | .005 | |||||
|
|
Onset of telemedicine usage | –0.20 (0.10) | –0.39 to –0.004 | –.06 | –2.01 (361) | .045 | |||||
|
|
Age | –0.001 (0.004) | –0.01 to 0.01 | –.01 | –0.27 (361) | .79 | |||||
|
|
Usefulness (general) | 0.14 (0.05) | 0.04 to 0.23 | .11 | 2.90 (361) | .004 | |||||
|
|
Usefulness (COVID-19) | 0.05 (0.08) | –0.10 to 0.20 | .03 | 0.69 (361) | .49 | |||||
|
|
Ease of use | 0.01 (0.003) | 0.004 to 0.02 | .11 | 3.27 (361) | .001 | |||||
|
|
Social influence | 0.72 (0.04) | 0.65 to 0.79 | .69 | 20.30 (361) | <.001 | |||||
| Step 5 | |||||||||||
|
|
Constant | –1.39 (0.46) | –2.29 to –0.48 | Reference | –3.02 (360) | .003 | |||||
|
|
Telemedicine caseload | 0.36 (0.12) | 0.12 to 0.59 | .10 | 2.94 (360) | .004 | |||||
|
|
Onset of telemedicine usage | –0.18 (0.10) | –0.37 to 0.01 | –.06 | –1.82 (360) | .07 | |||||
|
|
Age | –0.001 (0.004) | –0.01 to 0.01 | –.01 | –0.26 (360) | .79 | |||||
|
|
Usefulness (general) | 0.13 (0.05) | 0.03 to 0.22 | .10 | 2.65 (360) | .008 | |||||
|
|
Usefulness (COVID-19) | 0.03 (0.08) | –0.12 to 0.18 | .02 | 0.42 (360) | .68 | |||||
|
|
Ease of use | 0.01 (0.004) | 0.00 to 0.01 | .08 | 2.08 (360) | .04 | |||||
|
|
Social influence | 0.71 (0.04) | 0.64 to 0.78 | .68 | 20.26 (360) | <.001 | |||||
|
|
Facilitating conditions | 0.14 (0.07) | 0.002 to 0.28 | .08 | 1.99 (360) | .047 | |||||